Back to News
Market Impact: 0.25
UroGen Initiates Phase 1 Trial Of Next-Generation Bladder Cancer Therapy UGN-501
Source: Nasdaq
Healthcare & Biotech
UroGen Pharma announced that the first patient has been dosed in the Phase 1 trial of UGN-501, an investigational next-generation oncolytic virus for non-muscle invasive bladder cancer. The article excerpt provides no additional trial details or efficacy results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
URGN0.45
More News
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- RA Capital Management sells $9.13M in Lenz Therapeutics shares
- Karyopharm stock rating cut to neutral by Rodman on bankruptcy
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Bright Minds shares fall as BTIG cuts price target on clinical hold
- Vertex Pharma meets Q3 estimates, raises revenue guidance